Planning Board Proposes Postmarket Device Surveillance Timeline
This article was originally published in The Gray Sheet
A planning board created to develop a framework for a new U.S. medical device surveillance system has proposed a seven year plan on how to get the system up and running, which will include creating incentive systems for stakeholders as well as reducing the burden of recording and managing device data.
You may also be interested in...
CDRH Director Jeff Shuren says FDA is willing to foot the bill for a coordinating center to help launch a new "national device evaluation system," but it is contingent on a guarantee that the program would be funded by the upcoming user fee reauthorization.
Industry is increasingly supporting the "Sentinel" system for tracking postmarket product performance with claims and other real-world tools. But more companies need to be convinced of the value of the effort in advancing development of next-generation products, rather than simply a tool for safety surveillance, FDA Commissioner Robert Califf told members of the Alliance for a Stronger FDA.
A final order from FDA calls for manufacturers to submit PMAs or take their metal-on-metal hip devices off the market by May 18. The widely anticipated move is part of a broader response to elevated adverse event rates tied to the products.